NMDAR2B tyrosine phosphorylation regulates anxiety-like behavior and CRF expression in the amygdala
© Delawary et al; licensee BioMed Central Ltd. 2010
Received: 11 November 2010
Accepted: 30 November 2010
Published: 30 November 2010
Anxiety disorders are a highly prevalent and disabling class of psychiatric disorders. There is growing evidence implicating the glutamate system in the pathophysiology and treatment of anxiety disorders, though the molecular mechanism by which the glutamate system regulates anxiety-like behavior remains unclear.
In this study, we provide evidence suggesting that tyrosine phosphorylation of the NMDA receptor, an ionotropic glutamate receptor, contributes to anxiety-like behavior. The GluN2B subunit of the NMDA receptor is tyrosine-phosphorylated: Tyr-1472 is the major phosphorylation site. Homozygous knock-in mice that express a Tyr-1472-Phe mutant of GluN2B, which prevents phosphorylation of this site, show enhanced anxiety-like behavior in the elevated plus-maze test. Expression of corticotropin-releasing factor (CRF), which is important for the regulation of anxiety-like behavior, is increased in the amygdala of the knock-in mice. Furthermore, injection of CRF receptor antagonist attenuated the enhanced anxiety-like behavior of the knock-in mice. We also show that elevated plus-maze exposure simultaneously induced de-phosphorylation of Tyr-1472 and increased CRF expression.
These data suggest that Tyr-1472 phosphorylation on GluN2B is important for anxiety-like behavior by negative regulation of CRF expression in the amygdala.
Anxiety is commonly experienced and typically adaptive; however, excessive and dysfunctional anxiety leads to serious disorders. Anxiety disorders are the most prevalent class of psychiatric disorders in many countries . Compounds that target of γ-aminobutyric acid and the serotonergic systems have received great attention within the development of treatments for anxiety disorders . As some forms of anxiety are relatively resistant to treatment with these compounds, which include benzodiazepines and selective serotonin reuptake inhibitors, it has become increasingly apparent that alternative treatment strategies are needed. Recently, the glutamatergic system, the major mediator of excitatory synaptic transmission in the mammalian brain, has been the focus of pathophysiological studies of human anxiety disorders . In rodents, N-methyl-D-aspartate (NMDA) receptor antagonists show anxiolytic effects in several test scenarios including the elevated plus-maze test [4, 5]. While these reports point to the involvement of NMDA receptor-mediated signaling in the regulation of anxiety-like behaviors, molecular dissection of the role of NMDA receptor-mediated signaling is difficult because glutamate exerts its effects on various neural functions in a highly complex manner .
The NMDA receptor is crucial for neural development, synaptic plasticity, neuronal excitotoxicity, and behavior [6–9]. The NMDA receptor is composed of the GluN1 and GluN2 subunits: the GluN1 subunit is essential for the function of NMDAR channels, whereas the GluN2 subunits (GluN2A, GluN2B, GluN2C, and GluN2D) determine the characteristics of NMDAR channels by forming different heteromeric configurations with the GluN1 subunit . The function of NMDA receptor-mediated signaling is in part regulated by Src tyrosine kinase-mediated phosphorylation of the GluN2 subunit [10, 11]. Previous studies have found that Tyr-1325 and Tyr-1472 are the principal tyrosine phosphorylation sites on the GluN2A and the GluN2B subunits, respectively [12, 13]. Genetically engineered mice expressing the Y1325F mutation of GluN2A show antidepressant-like behavior, but their other neural functions, such as hippocampal-dependent learning, are normal . Alternatively, mice expressing the Y1472F mutation of GluN2B show a selective impairment in amygdala-dependent fear-learning . Considering the versatile role of the NMDA receptor in various neural functions , the phenotypes of these mutant mice are milder than expected: thus these mice provide valuable models in which to dissect the molecular basis of specific behaviors including anxiety-like behavior.
Corticotropin-releasing factor (CRF), which is highly abundant in the amygdala as well as in the paraventricular nucleus of the hypothalamus, plays an important role in regulating anxiety-like behavior . Patients suffering from anxiety disorders often have increased CRF levels in their cerebrospinal fluid [15, 16]. In rodents, intracerebro-ventricular delivery of CRF is anxiogenic . Likewise, transgenic mice overexpressing CRF exhibit increased anxiety-like behavior . Conversely, CRF1 receptor knockout mice have reduced anxiety . Injection of CRF antagonists or CRF1 receptor antisense oligonucleotide into the amygdala reduces stress-induced anxiety-like behavior [19, 20]. These results collectively show that CRF plays a key role in the regulation of anxiety-like behavior particularly in the amygdala. Therefore understanding the molecular mechanism of the regulation of CRF expression in the amygdala is important.
In the present study, using behavioral, pharmacological, and biochemical approaches with knock-in mice in which the Tyr-1472 of GluN2B is mutated to phenylalanine (GluN2B-YF), we have identified Tyr-1472 phosphorylation as a regulator of CRF mRNA expression and anxiety-like behavior.
Enhanced anxiety-like behavior of GluN2B-YF mice
Increased CRF expression in the amygdala of GluN2B-YF mice
Attenuation of enhanced anxiety-like behavior of GluN2B-YF mice by CRF receptor antagonist
De-phosphorylation of Tyr-1472 and increased CRF expression in the amygdala of wild-type mice after the EPM test
Induction of de-phosphorylation of Tyr-1472 and increased CRF expression by NMDA receptor stimulation
We then examined whether NMDA receptor activity is involved in the regulation of CRF expression in the amygdala. Coronal sections including the amygdala were stimulated with 100 μM NMDA for 7 min, followed by a wash-out period of 15 min. Then, the amygdala was rapidly dissected out and RNA was isolated to examine the level of CRF mRNA expression (Figure 4C). We found that NMDA receptor stimulation increased CRF mRNA expression in wild-type slices (control: 100.0 ± 10.5%, n = 6; NMDA stimulation: 160.1 ± 20.3%, n = 6; p < 0.05, Student's t-test). Interestingly, the same stimulation also induced de-phosphorylation of GluN2B Tyr-1472 (the level of Tyr-1472 phosphorylation: control, 100.0 ± 5.8%, n = 5; NMDA stimulation, 42.5 ± 3.1%, n = 5; p < 0.05, Student's t-test) (Figure 4D). In contrast to wild-type slices, CRF mRNA expression levels in the slices from GluN2B-YF mice were virtually unchanged by the same NMDA stimulation (control: 153.3 ± 20.5%, n = 6; NMDA stimulation: 143.1 ± 7.5%, n = 6; p > 0.2, Student's t-test) (Figure 4C). Thus, NMDA receptor stimulation is a likely trigger for increased CRF mRNA expression through de-phosphorylation of Tyr-1472 in the amygdala.
In this study, we showed that Tyr-1472 phosphorylation of GluN2B is a negative regulator of CRF mRNA expression in the amygdala. Behaviorally, deficient Tyr-1472 phosphorylation leads to enhanced anxiety-like behavior, which is consistent with enhanced CRF signaling [14, 17, 18]. We further demonstrated that acute intraperitoneal injection of NBI 27914, a selective CRF1 receptor antagonist, attenuated the anxiety-like behavior of GluN2B-YF mice. Given the established role of CRF in anxiety [14, 16, 17], it is likely that the enhanced anxiety phenotype observed in GluN2B-YF mice is linked to increased CRF expression in the amygdala.
Considering that Tyr-1472 phosphorylation is required for the NMDA receptor-mediated signaling , the present finding that GluN2B-YF mice exhibit increased anxiety-like behavior is consistent with previous pharmacological and genetic studies in rodents showing the anxiolytic-like effects of NMDA receptor blockade [24, 25]. Strikingly, intra-amygdala injection of an NMDA receptor antagonist, MK-801, prevents stress-induced increases in anxiety-like behavior in the EPM test , suggesting that NMDA receptors, especially in the amygdala, play a key role in regulating anxiety-like behavior. Interestingly, we found that the level of CRF was markedly increased in the amygdala of GluN2B-YF mice but not in other brain regions such as the hippocampus, cerebellum, and hypothalamus (Figure 2B-D). Thus, the Tyr-1472 phosphorylation-dependent regulation of NMDA receptors in the amygdala is likely to be responsible for anxiety-like behavior. Tissue specific conditional GluN2B-YF mice would be useful for analyzing the differential roles of Tyr-1472 phosphorylation.
CRF in the amygdala contributes to anxiety because injection of CRF antagonists or CRF1 receptor antisense oligonucleotides into the amygdala reduces anxiety-like behavior in rats [19, 20]. In amygdala-derived neuronal cultures, NMDA receptor stimulation induces CRF release , suggesting that a functional NMDA receptor system regulates CRF signaling in the amygdala. In this study, we found that the YF mutation in the Tyr-1472 phosphorylation site leads to increased CRF mRNA expression (Figure 2). Correlating with this, NMDA receptor stimulation induced tyrosine de-phosphorylation of Tyr-1472 and up-regulation of CRF mRNA expression in amygdala slices (Figure 4). Thus, Tyr-1472 phosphorylation links NMDA receptor activity and CRF expression in the amygdala: however, the mechanisms underlying enhanced CRF mRNA expression in GluN2B-YF mice remain to be determined. We previously found that Tyr-1472 phosphorylation regulates NMDA receptor-mediated CaMKII signaling in the amygdala . A simple model would predict that downstream NMDA receptor-mediated CaMKII signaling regulates CRF mRNA expression in the amygdala.
One major neuroendocrine system underlying an individual's capacity to cope with stress is the HPA axis . Besides the regulation of anxiety-like behavior, CRF is a key coordinator of the HPA axis and an essential component in the mediation of behavioral responses to stress . In contrast to the increased CRF levels in the amygdala (Figure 2A), we did not find any significant differences in hypothalamic CRF levels between GluN2B-YF mice and WT mice (Figure 2D). Consistent with these findings, the basal levels of plasma ACTH in GluN2B-YF mice were virtually unchanged compared to those of WT mice (Figure 2F). Thus, the function of Tyr-1472 phosphorylation may be different between brain regions. Alternatively, in the hypothalamus, some compensatory event might have occurred to mask the hypothalamic phenotypes in GluN2B-YF mice.
There is widespread interest in CRF1 receptor antagonists for the treatment of anxiety disorders [21, 27]: however, these potential therapies can influence the function of the HPA axis in response to stress . Tyr-1472 phosphorylation in GluN2B regulates anxiety-like behavior through regulation of amygdaloid CRF expression without altering the function of the HPA axis. Therefore, blocking Tyr-1472 phosphorylation in the amygdala may be a clinically effective means of treating anxiety disorders without the potential risks associated with blocking of the function of the HPA axis.
In summary, the present study demonstrates that the cellular interaction between CRF signaling and NMDA receptors, especially Tyr-1472 phosphorylation of GluN2B, is necessary for the regulation of anxiety-like behavior. GluN2B-YF mice should serve as a useful animal model to study the pathogenesis of anxiety disorders and to develop therapeutic drugs for the disease.
Heterozygous GluN2B-YF mice  were successively backcrossed to C57BL/6J mice to yield subsequent generations with a pure C57BL/6J genetic background. F10 heterozygous mice were crossed to each other to yield homozygous mice and wild-type littermates. Male 8-12-week old mice were used in this study. All experiments and analyses were done in a completely blind manner. Experiments with animals were carried out in accordance with the guidelines for animal use issued by the Committee of Animal Experiments, Institute of Medical Science, University of Tokyo.
Elevated plus-maze (EPM) test
The elevated plus-maze test (EP-3002; O' Hara & Co., Ltd., Tokyo, Japan) consisted of two open arms (25 × 5 cm) and two enclosed arms of the same size extending from a central area (5 × 5 cm) and elevated 50 cm from the ground. The ambient light level was 30 lux. The mice were placed in the central square of the maze facing one of the open arms. Mouse behavior was recorded during a 10 min test period with a Macintosh computer using Image EP 2.13× and Image EPC 2.03s× (O'Hara & Co., Ltd.), a modified software based on the public domain of NIH Image program. The following conventional parameters were recorded: the number of entries into open or closed arms and the time spent in open or closed arms.
Mice were anesthetized with halothane and immediately decapitated. Brains were then rapidly removed and frozen by liquid nitrogen. Serial coronal sections (400 μm thickness) were cryosectioned, and the various brain regions were collected with a biopsy puncher. Total RNA was isolated from the brain regions and reverse transcribed with Superscript III (Invitrogen, Carlsbad, CA, USA). Real-time PCR was performed with TaqMan primers on an ABI PRISM 7900HT system (Applied Biosystems, Foster City, CA, USA) according to the supplier's protocol. The following intron-spanning primer sets were used: HPRT (internal control), Mm0046968_m1; CRF, Mm01293920_S1 (Applied Biosystems). Relative expression levels were determined according to the 2-ΔΔCt method (Applied Biosystems, User Bulletin).
Measurements of CRF protein level
Serial coronal sections (200 μm) were cryosectioned, and the amygdalae were collected . CRF protein levels were measured by using an enzyme-linked immunoassay kit (Mouse/Rat CRF-HS ELISA kit (YK131), Yanaihara Institute Inc., Shizuoka, Japan) according to the supplier's protocol.
Measurements of plasma adrenocorticotropin-releasing hormone (ACTH) levels
Mice were killed by rapid decapitation, and blood was collected at around 9:00 AM. Serum was isolated and frozen at -80°C until analysis. Basal plasma ACTH levels were measured using an enzyme-linked immunoassay (SRL Inc., Tokyo, Japan).
Intraperitoneal injection of CRF1 receptor antagonist
A non-peptide selective CRF1 receptor antagonist, NBI 27914 (dissolved at 10 mg/ml in DMSO, 10 mg/kg body weight, Tocris, Bristol, UK)  or vehicle (DMSO) was injected intraperitoneally 45 min before the EPM test.
Pharmacological treatment of brain slices
Coronal slices including the amygdala (400 μm thickness) were prepared from 8- to 10-week-old mice and placed in an interface-type holding chamber for at least 3 h. Slices were preincubated in ACSF  for 1 h and then stimulated with 100 μM NMDA for 7 min.
Preparation of lysate, immunoprecipitation and immunoblotting
Preparation of lysate from the mouse brain and immunoblotting were performed as described previously . For quantification, the immunoreacted protein bands were analyzed with the NIH image software. The rabbit polyclonal antibody against phospho-Tyr-1472/GluN2B was described previously . The mouse monoclonal antibody against GluN2B was purchased from Millipore (Billerica, MA, USA).
All data are expressed as the means ± SEM. Statistical analysis was performed using Student's t test, one-way ANOVA, two-way ANOVA, and Tukey's post hoc test. Differences with p < 0.05 were considered as significant.
analysis of variance
This research was supported in part by Grants-in-Aid for Scientific Research (T.N., T.Y., and T.M.), by the Global COE Program (Integrative Life Science Based on the Study of Biosignaling Mechanisms) (T.Y.), by the Global COE Program (Comprehensive Center of Education and Research for Chemical Biology of the Diseases) (T.M.), and the Strategic Research Program for Brain Sciences (T.M.) from the Japan Society for the Promotion of Science and the Ministry of Education, Science, Sports, Culture and Technology of Japan.
- Alonso J, Lepine JP: Overview of key data from the European study of the epidemiology of mental disorders (ESEMeD). J Clin Psychiatry. 2007, 68: 3-9. 10.4088/JCP.0207e03.View ArticlePubMedGoogle Scholar
- Salzman C, Miyawaki EK, le Bars P, Kerrihand TN: Neurobiologic basis of anxiety and its treatment. Harv Rev Psychiatry. 1993, 1: 197-206. 10.3109/10673229309017080.View ArticlePubMedGoogle Scholar
- Cortese BM, Phan KL: The role of glutamate in anxiety and related disorders. CNS Spectr. 2005, 10: 820-830.PubMedGoogle Scholar
- Martinez G, Ropero C, Funes A, Flores E, Blotta C, Landa AI, Gargiulo PA: Effects of selective NMDA and non-NMDA blockade in the nucleus accumbens on the plus-maze test. Physiol Behav. 2002, 76: 219-224. 10.1016/S0031-9384(02)00704-7.View ArticlePubMedGoogle Scholar
- Wiley JL, Cristello AF, Balster RL: Effects of site-selective NMDA receptor antagonists in an elevated plus-maze model of anxiety in mice. Eur J Pharmacol. 1995, 294: 101-107. 10.1016/0014-2999(95)00506-4.View ArticlePubMedGoogle Scholar
- Cull-Candy S, Brickley S, Farrant M: NMDA receptor subunits: diversity, development and disease. Curr Opin Neurobiol. 2001, 11: 327-335. 10.1016/S0959-4388(00)00215-4.View ArticlePubMedGoogle Scholar
- Choi DW: Calcium-mediated neurotoxicity: relationship to specific channel types and role in ischemic damage. Trends Neurosci. 1988, 11: 465-469. 10.1016/0166-2236(88)90200-7.View ArticlePubMedGoogle Scholar
- McDonald JW, Johnston MV: Physiological and pathophysiological roles of excitatory amino acids during central nervous system development. Brain Res Rev. 1990, 15: 41-70. 10.1016/0165-0173(90)90011-C.View ArticlePubMedGoogle Scholar
- Collingridge GL, Bliss TVP: Memories of NMDA receptors and LTP. Trends Neurosci. 1995, 18: 54-56. 10.1016/0166-2236(95)93868-X.View ArticlePubMedGoogle Scholar
- Salter MW, Kalia LV: Src kinases: a hub for NMDA receptor regulation. Nat Rev Neurosci. 2004, 5: 317-328. 10.1038/nrn1368.View ArticlePubMedGoogle Scholar
- Chen BS, Roche KW: Regulation of NMDA receptors by phosphorylation. Neuropharmacol. 2007, 53: 362-368. 10.1016/j.neuropharm.2007.05.018.View ArticleGoogle Scholar
- Taniguchi S, Nakazawa T, Tanimura A, Kiyama Y, Tezuka T, Watabe AM, Katayama N, Yokoyama K, Inoue T, Izumi-Nakaseko H, Kakuta S, Sudo K, Iwakura Y, Umemori H, Inoue T, Murphy NP, Hashimoto K, Kano M, Manabe T, Yamomoto T: Involvement of NMDAR2A tyrosine phosphorylation in depression-related behavior. EMBO J. 2009, 28: 3717-3729. 10.1038/emboj.2009.300.PubMed CentralView ArticlePubMedGoogle Scholar
- Nakazawa T, Komai S, Watabe AM, Kiyama Y, Fukaya M, Arima-Yoshida F, Horai R, Sudo K, Ebine K, Delawary M, Goto J, Umemori H, Tezuka T, Iwakura Y, Watanabe M, Yamamoto T, Manabe T: NR2B tyrosine phosphorylation modulates fear learning as well as amygdaloid synaptic plasticity. EMBO J. 2006, 25: 2867-2877. 10.1038/sj.emboj.7601156.PubMed CentralView ArticlePubMedGoogle Scholar
- Keck ME: Corticotropin-releasing factor, vasopressin and receptor systems in depression and anxiety. Amino Acids. 2006, 31: 241-250. 10.1007/s00726-006-0333-y.View ArticlePubMedGoogle Scholar
- Koob GF, Heinrichs SC: A role for corticotrophin releasing factor and urocortin in behavioral responses to stressors. Brain Res. 1999, 848: 141-152. 10.1016/S0006-8993(99)01991-5.View ArticlePubMedGoogle Scholar
- Reul JM, Holsboer F: Corticotropin-releasing factor receptors 1 and 2 in anxiety and depression. Curr Opin Pharmacol. 2002, 2: 23-33. 10.1016/S1471-4892(01)00117-5.View ArticlePubMedGoogle Scholar
- Bale TL, Vale WW: CRF and CRF receptors: role in stress responsivity and other behaviors. Annu Rev Pharmacol Toxicol. 2004, 44: 525-557. 10.1146/annurev.pharmtox.44.101802.121410.View ArticlePubMedGoogle Scholar
- Strenzel-Poore MP, Heinrichs SC, Rivest S, Koob GF, Vale WW: Overproduction of corticotrophin-releasing factor in transgenic mice: a genetic model of anxiogenic behavior. J Neurosci. 1994, 14: 2579-2584.Google Scholar
- Heinrichs SC, Pich EM, Miczek KA, Britton KT, Koob GF: Corticotropin-releasing factor antagonist reduces emotionality in socially defeated rats via direct neurotropic action. Brain Res. 1992, 581: 190-197. 10.1016/0006-8993(92)90708-H.View ArticlePubMedGoogle Scholar
- Liebsch G, Landgraf R, Gerstberger R, Probst JC, Wotjak CT, Engelmann M, Holsboer F, Montkowski A: Chronic infusion of a CRH1 receptor antisense oligodeoxynucleotide into the central nucleus of the amygdala reduced anxiety-related behavior in socially defeated rats. Regul Pept. 1995, 59: 229-239. 10.1016/0167-0115(95)00099-W.View ArticlePubMedGoogle Scholar
- Korte SM, De Boer SF: A robust animal model of state anxiety: fear-potentiated behavior in the elevated plus-maze. Eur J Pharmacol. 2003, 463: 163-175. 10.1016/S0014-2999(03)01279-2.View ArticlePubMedGoogle Scholar
- Holmes A: Targeted gene mutation approaches to the study of anxiety-like behavior in mice. Neurosci Biobehav Rev. 2001, 25: 261-273. 10.1016/S0149-7634(01)00012-4.View ArticlePubMedGoogle Scholar
- Mathew SJ, Price RB, Charney DS: Recent advances in the neurobiology of anxiety disorders. Am J Med Genet Part C Semin Med Genet. 2008, 148C: 89-98. 10.1002/ajmg.c.30172.View ArticlePubMedGoogle Scholar
- Boyce-Rustay JM, Holmes A: Genetic inactivation of the NMDA receptor NR2A subunit has anxiolytic- and antidepressant-like effects in mice. Neuropsychopharmacol. 2006, 31: 2405-2414. 10.1038/sj.npp.1301039.View ArticleGoogle Scholar
- Adamec RE, Burton P, Shallow T, Budgell J: Unilateral block of NMDA receptors in the amygdala prevents predator stress-induced lasting increases in anxiety-like behavior and unconditioned startle-effective hemisphere depends on the behavior. Physiol Behav. 1999, 65: 739-751. 10.1016/S0031-9384(98)00225-X.View ArticlePubMedGoogle Scholar
- Cratty MS, Birkle DL: N-methyl-D-aspartate (NMDA)-mediated corticotropin-releasing factor (CRF) release in cultured rat amygdala neurons. Peptides. 1999, 20: 93-100. 10.1016/S0196-9781(98)00147-8.View ArticlePubMedGoogle Scholar
- Holmes A, Heilig M, Rupniak NM, Steckler T, Griebel G: Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders. Trends Pharmacol Sci. 2003, 24: 580-588. 10.1016/j.tips.2003.09.011.View ArticlePubMedGoogle Scholar
- Habib KE, Weld KP, Rice KC, Pushkas J, Champoux M, Listwak S, Webster EL, Atkinson AJ, Schulkin J, Contoreggi C, Chrousos GP, McCann SM, Suomi SJ, Higley JD, Gold PW: Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates. Proc Natl Acad Sci USA. 2000, 97: 6079-6084. 10.1073/pnas.97.11.6079.PubMed CentralView ArticlePubMedGoogle Scholar
- Murphy NP, Maidment NT: Orphanin FQ/nociceptin modulation of mesolimbic dopamine transmission determined by microdialysis. J Neurochem. 1999, 73: 179-186. 10.1046/j.1471-4159.1999.0730179.x.View ArticlePubMedGoogle Scholar
- Baram TZ, Chalmers DT, Chen C, Koutsoukos Y, De Souza EB: The CRF1 receptor mediates the excitatory actions of corticotropin releasing factor (CRF) in the developing rat brain: in vivo evidence using a novel, selective, non-peptide CRF receptor antagonist. Brain Res. 1997, 770: 89-95. 10.1016/S0006-8993(97)00759-2.PubMed CentralView ArticlePubMedGoogle Scholar
- Nakazawa T, Komai S, Tezuka T, Hisatsune C, Umemori H, Semba K, Mishina M, Manabe T, Yamamoto T: Characterization of Fyn-mediated tyrosine phosphorylation sites on GluRε2 (NR2B) subunit of the N-methyl-D-aspartate receptor. J Biol Chem. 2001, 276: 693-699. 10.1074/jbc.M008085200.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.